Endo-lysosomal and autophagic dysfunction: a driving factor in Alzheimer's disease?

Journal of Neurochemistry

Volumn 140, Issue 5, 2017, Pages 703-717

  Whyte, Lauren S ^a,b   Lau, Adeline A ^a   Hemsley, Kim M ^a   Hopwood, John J ^a   Sargeant, Timothy J ^a  

^a SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Alzheimer's disease; dementia; endosome; lysosomal storage disorder; lysosome; neurodegenerative disease

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; LYSOSOME ENZYME;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AUTOPHAGY; BIOACCUMULATION; BRAIN TISSUE; CELL DAMAGE; CYTOLOGY; DISEASE COURSE; ENDOCYTOSIS; ENDOSOME; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC VARIATION; HUMAN; HYDROLYSIS; LYSOSOME; MACROMOLECULE; MOLECULAR PATHOLOGY; NONHUMAN; PATHOGENESIS; PHENOTYPIC VARIATION; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN TRANSPORT; REVIEW; STORAGE DISEASE; ANIMAL; LYSOSOME STORAGE DISEASE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; AUTOPHAGY; HUMANS; LYSOSOMAL STORAGE DISEASES, NERVOUS SYSTEM; LYSOSOMES;

EID: 85013783924     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13935     Document Type: Review

References (174)

1. Adalbert R., Nogradi A., Babetto E., Janeckova L., Walker S. A., Kerschensteiner M., Misgeld T. and Coleman M. P. (2009) Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies. Brain 132, 402–416.
2. Albert M. S. (2011) Changes in cognition. Neurobiol. Aging 32(Suppl 1), S58–S63.
3. Alcalay R. N., Dinur T., Quinn T. et al. (2014) Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol. 71, 752–757.
4. Almeida O. P., Hulse G. K., Lawrence D. and Flicker L. (2002) Smoking as a risk factor for Alzheimer's disease: contrasting evidence from a systematic review of case-control and cohort studies. Addiction 97, 15–28.
5. Alzheimer A. (1906) Über einen eigenartigen schweren Erkrankungsprozeβ der Hirnrinde. Neurol. Central. 25, 1134.
6. Andersen O. M., Reiche J., Schmidt V. et al. (2005) Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc. Natl Acad. Sci. USA 102, 13461–13466.
7. Annunziata I., Patterson A., Helton D., Hu H., Moshiach S., Gomero E., Nixon R. and d'Azzo A. (2013) Lysosomal NEU1 deficiency affects amyloid precursor protein levels and amyloid-beta secretion via deregulated lysosomal exocytosis. Nat. Commun., 4, 2734.
8. Ariga T., Yanagisawa M., Wakade C., Ando S., Buccafusco J. J., McDonald M. P. and Yu R. K. (2010) Ganglioside metabolism in a transgenic mouse model of Alzheimer's disease: expression of Chol-1alpha antigens in the brain. ASN Neuro. 2, e00044.
9. Armstrong A., Mattsson N., Appelqvist H. et al. (2014) Lysosomal network proteins as potential novel CSF biomarkers for Alzheimer's disease. NeuroMol. Med. 16, 150–160.
10. Barrier L., Ingrand S., Damjanac M., Rioux Bilan A., Hugon J. and Page G. (2007) Genotype-related changes of ganglioside composition in brain regions of transgenic mouse models of Alzheimer's disease. Neurobiol. Aging 28, 1863–1872.
11. Beebe R. T. and Formel P. F. (1954) Gargoylism: sex-linked transmission in nine males. Trans. Am. Clin. Climatol. Assoc. 66, 199–207.
12. Bekris L. M., Yu C. E., Bird T. D. and Tsuang D. W. (2010) Genetics of Alzheimer disease. J. Geriatr. Psychiatry Neurol. 23, 213–227.
13. Benussi L., Binetti G., Sina E., Gigola L., Bettecken T., Meitinger T. and Ghidoni R. (2008) A novel deletion in progranulin gene is associated with FTDP-17 and CBS. Neurobiol. Aging 29, 427–435.
14. Bernardo A., Harrison F. E., McCord M. et al. (2009) Elimination of GD3 synthase improves memory and reduces amyloid-beta plaque load in transgenic mice. Neurobiol. Aging, 30, 1777–1791.
15. Bernstein H. G., Bruszis S., Schmidt D., Wiederanders B. and Dorn A. (1989) Immunodetection of cathepsin D in neuritic plaques found in brains of patients with dementia of Alzheimer type. J. Hirnforsch. 30, 613–618.
16. Boland B., Smith D. A., Mooney D., Jung S. S., Walsh D. M. and Platt F. M. (2010) Macroautophagy is not directly involved in the metabolism of amyloid precursor protein. J. Biol. Chem. 285, 37415–37426.
17. Boots E. A., Schultz S. A., Oh J. M. et al. (2015) Cardiorespiratory fitness is associated with brain structure, cognition, and mood in a middle-aged cohort at risk for Alzheimer's disease. Brain Imaging Behav. 9, 639–649.
18. Braak H. and Braak E. (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239–259.
19. Bright N. A., Davis L. J. and Luzio J. P. (2016) Endolysosomes are the principal intracellular sites of acid hydrolase activity. Curr. Biol. 26, 2233–2245.
20. Calamai M. and Pavone F. S. (2013) Partitioning and confinement of GM1 ganglioside induced by amyloid aggregates. FEBS Lett. 587, 1385–1391.
21. Caporaso G. L., Gandy S. E., Buxbaum J. D. and Greengard P. (1992) Chloroquine inhibits intracellular degradation but not secretion of Alzheimer beta/A4 amyloid precursor protein. Proc. Natl Acad. Sci. USA 89, 2252–2256.
22. Cataldo A. M. and Nixon R. A. (1990) Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. Proc. Natl Acad. Sci. USA 87, 3861–3865.
23. Cataldo A. M., Paskevich P. A., Kominami E. and Nixon R. A. (1991) Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease. Proc. Natl Acad. Sci. USA 88, 10998–11002.
24. Cataldo A. M., Barnett J. L., Mann D. M. and Nixon R. A. (1996) Colocalization of lysosomal hydrolase and beta-amyloid in diffuse plaques of the cerebellum and striatum in Alzheimer's disease and Down's syndrome. J. Neuropathol. Exp. Neurol. 55, 704–715.
25. Cataldo A. M., Barnett J. L., Pieroni C. and Nixon R. A. (1997) Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J. Neurosci. 17, 6142–6151.
26. Cataldo A. M., Peterhoff C. M., Troncoso J. C., Gomez-Isla T., Hyman B. T. and Nixon R. A. (2000) Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 157, 277–286.
27. Cataldo A. M., Petanceska S., Peterhoff C. M., Terio N. B., Epstein C. J., Villar A., Carlson E. J., Staufenbiel M. and Nixon R. A. (2003) App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. J. Neurosci. 23, 6788–6792.
28. Cataldo A. M., Petanceska S., Terio N. B., Peterhoff C. M., Durham R., Mercken M., Mehta P. D., Buxbaum J., Haroutunian V. and Nixon R. A. (2004) Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol. Aging 25, 1263–1272.
29. Cataldo A. M., Mathews P. M., Boiteau A. B., Hassinger L. C., Peterhoff C. M., Jiang Y., Mullaney K., Neve R. L., Gruenberg J. and Nixon R. A. (2008) Down syndrome fibroblast model of Alzheimer-related endosome pathology: accelerated endocytosis promotes late endocytic defects. Am. J. Pathol. 173, 370–384.
30. Cataldo J. K., Prochaska J. J. and Glantz S. A. (2010) Cigarette smoking is a risk factor for Alzheimer's Disease: an analysis controlling for tobacco industry affiliation. J. Alzheimers Dis. 19, 465–480.
31. Chan R. B., Oliveira T. G., Cortes E. P., Honig L. S., Duff K. E., Small S. A., Wenk M. R., Shui G. and Di Paolo G. (2012) Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J. Biol. Chem. 287, 2678–2688.
32. Chávez-Gutiérrez L., Bammens L., Benilova I. et al. (2012) The mechanism of γ-Secretase dysfunction in familial Alzheimer disease. EMBO J. 31, 2261–2274.
33. Choi S., Kim D., Kam T. I. et al. (2015) Lysosomal Enzyme Glucocerebrosidase Protects against Abeta1-42 Oligomer-Induced Neurotoxicity. PLoS ONE 10, e0143854.
34. Clark L. N., Chan R., Cheng R. et al. (2015) Gene-wise association of variants in four lysosomal storage disorder genes in neuropathologically confirmed Lewy body disease. PLoS ONE 10, e0125204.
35. Clayton E. L., Mizielinska S., Edgar J. R. et al. (2015) Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathology. Acta Neuropathol. 130, 511–523.
36. Coen K., Flannagan R. S., Baron S. et al. (2012) Lysosomal calcium homeostasis defects, not proton pump defects, cause endo-lysosomal dysfunction in PSEN-deficient cells. J. Cell Biol. 198, 23–35.
37. Cole G. M., Huynh T. V. and Saitoh T. (1989) Evidence for lysosomal processing of amyloid beta-protein precursor in cultured cells. Neurochem. Res. 14, 933–939.
38. Cole G. M., Bell L., Truong Q. B. and Saitoh T. (1992) An endosomal-lysosomal pathway for degradation of amyloid precursor protein. Ann. N. Y. Acad. Sci. 674, 103–117.
39. Condello C., Schain A. and Grutzendler J. (2011) Multicolor time-stamp reveals the dynamics and toxicity of amyloid deposition. Sci. Rep. 1, 19.
40. Cormont M., Metón I., Mari M., Monzo P., Keslair F., Gaskin C., McGraw T. E. and Le Marchand-Brustel Y. (2003) CD2AP/CMS regulates endosome morphology and traffic to the degradative pathway through its interaction with Rab4 and c-Cbl. Traffic 4, 97–112.
41. D'Andrea M. R., Nagele R. G., Wang H. Y., Peterson P. A. and Lee D. H. (2001) Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology 38, 120–134.
42. Di Fruscio G., Schulz A., De Cegli R., Savarese M., Mutarelli M., Parenti G., Banfi S., Braulke T., Nigro V. and Ballabio A. (2015) Lysoplex: an efficient toolkit to detect DNA sequence variations in the autophagy-lysosomal pathway. Autophagy 11, 928–938.
43. Duffner P. K., Caggana M., Orsini J. J. et al. (2009) Newborn screening for Krabbe disease: the New York State model. Pediatr. Neurol., 40, 245–252; discussion 253-245.
44. Edgar J. R., Willen K., Gouras G. K. and Futter C. E. (2015) ESCRTs regulate amyloid precursor protein sorting in multivesicular bodies and intracellular amyloid-beta accumulation. J. Cell Sci. 128, 2520–2528.
45. Emiliani C., Urbanelli L., Racanicchi L., Orlacchio A., Pelicci G., Sorbi S., Bernardi G. and Orlacchio A. (2003) Up-regulation of glycohydrolases in Alzheimer's Disease fibroblasts correlates with Ras activation. J. Biol. Chem. 278, 38453–38460.
46. Esch F. S., Keim P. S., Beattie E. C., Blacher R. W., Culwell A. R., Oltersdorf T., McClure D. and Ward P. J. (1990) Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 248, 1122–1124.
47. Esselens C., Oorschot V., Baert V. et al. (2004) Presenilin 1 mediates the turnover of telencephalin in hippocampal neurons via an autophagic degradative pathway. J. Cell Biol. 166, 1041–1054.
48. Fernandez M. A., Klutkowski J. A., Freret T. and Wolfe M. S. (2014) Alzheimer presenilin-1 mutations dramatically reduce trimming of long amyloid β-peptides (Aβ) by γ-secretase to increase 42-to-40-residue Aβ. J. Biol. Chem. 289, 31043–31052.
49. Filocamo M. and Morrone A. (2011) Lysosomal storage disorders: molecular basis and laboratory testing. Hum. Genomics 5, 156–169.
50. Flicker C., Bartus R. T., Crook T. H. and Ferris S. H. (1984) Effects of aging and dementia upon recent visuospatial memory. Neurobiol. Aging 5, 275–283.
51. Gatz M., Reynolds C. A., Fratiglioni L., Johansson B., Mortimer J. A., Berg S., Fiske A. and Pedersen N. L. (2006) Role of genes and environments for explaining Alzheimer disease. Arch. Gen. Psychiatry 63, 168–174.
52. Goetzl E. J., Boxer A., Schwartz J. B., Abner E. L., Petersen R. C., Miller B. L. and Kapogiannis D. (2015) Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. Neurology 85, 40–47.
53. Golde T. E., Estus S., Younkin L. H., Selkoe D. J. and Younkin S. G. (1992) Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science 255, 728–730.
54. Gowrishankar S., Yuan P., Wu Y., Schrag M., Paradise S., Grutzendler J., De Camilli P. and Ferguson S. M. (2015) Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques. Proc. Natl Acad. Sci. USA 112, E3699–E3708.
55. Grbovic O. M., Mathews P. M., Jiang Y., Schmidt S. D., Dinakar R., Summers-Terio N. B., Ceresa B. P., Nixon R. A. and Cataldo A. M. (2003) Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production. J. Biol. Chem. 278, 31261–31268.
56. Grimm M. O., Zinser E. G., Grosgen S. et al. (2012) Amyloid precursor protein (APP) mediated regulation of ganglioside homeostasis linking Alzheimer's disease pathology with ganglioside metabolism. PLoS ONE 7, e34095.
57. Gylys K. H., Fein J. A., Yang F., Miller C. A. and Cole G. M. (2007) Increased cholesterol in Abeta-positive nerve terminals from Alzheimer's disease cortex. Neurobiol. Aging 28, 8–17.
58. Haass C., Schlossmacher M. G., Hung A. Y. et al. (1992a) Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359, 322–325.
59. Haass C., Koo E. H., Mellon A., Hung A. Y. and Selkoe D. J. (1992b) Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 357, 500–503.
60. Haass C., Hung A. Y., Schlossmacher M. G., Teplow D. B. and Selkoe D. J. (1993) beta-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. J. Biol. Chem. 268, 3021–3024.
61. Hayashi H., Kimura N., Yamaguchi H. et al. (2004) A seed for Alzheimer amyloid in the brain. J. Neurosci. 24, 4894–4902.
62. Hers H. G. (1963) alpha-Glucosidase deficiency in generalized glycogen-storage disease (Pompe's disease). Biochem. J. 86, 11–16.
63. Hong S., Ostaszewski B. L., Yang T., O'Malley T. T., Jin M., Yanagisawa K., Li S., Bartels T. and Selkoe D. J. (2014) Soluble Abeta oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes. Neuron 82, 308–319.
64. Huse J. T., Pijak D. S., Leslie G. J., Lee V. M. and Doms R. W. (2000) Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase. J. Biol. Chem. 275, 33729–33737.
65. Hwu W. L., Chien Y. H., Lee N. C. et al. (2009) Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936 + 919G>A (IVS4 + 919G>A). Hum. Mutat. 30, 1397–1405.
66. Ii K., Ito H., Kominami E. and Hirano A. (1993) Abnormal distribution of cathepsin proteinases and endogenous inhibitors (cystatins) in the hippocampus of patients with Alzheimer's disease, parkinsonism-dementia complex on Guam, and senile dementia and in the aged. Virchows Arch A Pathol Anat Histopathol 423, 185–194.
67. Jarrett J. T., Berger E. P. and Lansbury P. T., Jr (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32, 4693–4697.
68. Jervis G. A. (1948) Early senile dementia in mongoloid idiocy. Am. J. Psychiatry 105, 102–106.
69. Jiang Y., Mullaney K. A., Peterhoff C. M., Che S., Schmidt S. D., Boyer-Boiteau A., Ginsberg S. D., Cataldo A. M., Mathews P. M. and Nixon R. A. (2010) Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc. Natl Acad. Sci. USA 107, 1630–1635.
70. Jin L. W., Shie F. S., Maezawa I., Vincent I. and Bird T. (2004) Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am. J. Pathol. 164, 975–985.
71. Jorm A. F., Korten A. E. and Henderson A. S. (1987) The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr. Scand. 76, 465–479.
72. Kagedal K., Kim W. S., Appelqvist H., Chan S., Cheng D., Agholme L., Barnham K., McCann H., Halliday G. and Garner B. (2010) Increased expression of the lysosomal cholesterol transporter NPC1 in Alzheimer's disease. Biochim. Biophys. Acta 1801, 831–838.
73. Kandalepas P. C., Sadleir K. R., Eimer W. A., Zhao J., Nicholson D. A. and Vassar R. (2013) The Alzheimer's beta-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta Neuropathol. 126, 329–352.
74. Keilani S., Lun Y., Stevens A. C. et al. (2012) Lysosomal dysfunction in a mouse model of Sandhoff disease leads to accumulation of ganglioside-bound amyloid-beta peptide. J. Neurosci. 32, 5223–5236.
75. Kim S., Sato Y., Mohan P. S., Peterhoff C., Pensalfini A., Rigoglioso A., Jiang Y. and Nixon R. A. (2016) Evidence that the rab5 effector APPL1 mediates APP-betaCTF-induced dysfunction of endosomes in Down syndrome and Alzheimer's disease. Mol. Psychiatry 21, 707–716.
76. Kinoshita A., Fukumoto H., Shah T., Whelan C. M., Irizarry M. C. and Hyman B. T. (2003) Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J. Cell Sci. 116, 3339–3346.
77. Koo E. H. and Squazzo S. L. (1994) Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 269, 17386–17389.
78. Kracun I., Rosner H., Drnovsek V., Heffer-Lauc M., Cosovic C. and Lauc G. (1991) Human brain gangliosides in development, aging and disease. Int. J. Dev. Biol. 35, 289–295.
79. Kracun I., Kalanj S., Talan-Hranilovic J. and Cosovic C. (1992) Cortical distribution of gangliosides in Alzheimer's disease. Neurochem. Int. 20, 433–438.
80. Kraepelin E. (1910) Psychiatrie. Ein Lehbuch für Studirrende und Äerzte. II. Band: Klinische Psychiatrie, I. Teil. Leipzig: Johann Ambrosius Barth Verlag.
81. Kreutz F., Scherer E. B., Ferreira A. G., Petry Fdos S., Pereira C. L., Santana F., de Souza Wyse A. T., Salbego C. G. and Trindade V. M. (2013) Alterations on Na(+), K(+)-ATPase and acetylcholinesterase activities induced by amyloid-beta peptide in rat brain and GM1 ganglioside neuroprotective action. Neurochem. Res. 38, 2342–2350.
82. Kuhn P. H., Wang H., Dislich B., Colombo A., Zeitschel U., Ellwart J. W., Kremmer E., Rossner S. and Lichtenthaler S. F. (2010) ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J. 29, 3020–3032.
83. Lambert J. C., Ibrahim-Verbaas C. A., Harold D. et al. (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet., 45, 1452–1458.
84. Langui D., Girardot N., El Hachimi K. H., Allinquant B., Blanchard V., Pradier L. and Duyckaerts C. (2004) Subcellular topography of neuronal Abeta peptide in APPxPS1 transgenic mice. Am. J. Pathol. 165, 1465–1477.
85. Lee J. H., Yu W. H., Kumar A. et al. (2010) Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 141, 1146–1158.
86. Lee S., Sato Y. and Nixon R. A. (2011) Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer's-like axonal dystrophy. J. Neurosci. 31, 7817–7830.
87. Lee S. H., Harold D., Nyholt D. R., Goddard M. E., Zondervan K. T., Williams J., Montgomery G. W., Wray N. R. and Visscher P. M. (2013) Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer's disease, multiple sclerosis and endometriosis. Hum. Mol. Genet. 22, 832–841.
88. Lin H. Y., Chong K. W., Hsu J. H. et al. (2009) High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ. Cardiovasc. Genet. 2, 450–456.
89. Lindsay J., Laurin D., Verreault R., Hebert R., Helliwell B., Hill G. B. and McDowell I. (2002) Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am. J. Epidemiol. 156, 445–453.
90. Liu R. Q., Zhou Q. H., Ji S. R., Zhou Q., Feng D., Wu Y. and Sui S. F. (2010) Membrane localization of beta-amyloid 1-42 in lysosomes: a possible mechanism for lysosome labilization. J. Biol. Chem. 285, 19986–19996.
91. Maday S., Wallace K. E. and Holzbaur E. L. (2012) Autophagosomes initiate distally and mature during transport toward the cell soma in primary neurons. J. Cell Biol. 196, 407–417.
92. Magini A., Polchi A., Tozzi A., Tancini B., Tantucci M., Urbanelli L., Borsello T., Calabresi P. and Emiliani C. (2015) Abnormal cortical lysosomal beta-hexosaminidase and beta-galactosidase activity at post-synaptic sites during Alzheimer's disease progression. Int. J. Biochem. Cell Biol. 58, 62–70.
93. Mann D. M. (1988) The pathological association between Down syndrome and Alzheimer disease. Mech. Ageing Dev. 43, 99–136.
94. Mann D. M. and Esiri M. M. (1989) The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J. Neurol. Sci. 89, 169–179.
95. Mathews P. M., Guerra C. B., Jiang Y. et al. (2002) Alzheimer's disease-related overexpression of the cation-dependent mannose 6-phosphate receptor increases Abeta secretion: role for altered lysosomal hydrolase distribution in beta-amyloidogenesis. J. Biol. Chem. 277, 5299–5307.
96. Mawuenyega K. G., Sigurdson W., Ovod V., Munsell L., Kasten T., Morris J. C., Yarasheski K. E. and Bateman R. J. (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330, 1774.
97. Meikle P. J., Hopwood J. J., Clague A. E. and Carey W. F. (1999) Prevalence of lysosomal storage disorders. JAMA 281, 249–254.
98. Mirra S. S., Hart M. N. and Terry R. D. (1993) Making the diagnosis of Alzheimer's disease. A primer for practicing pathologists. Arch. Pathol. Lab. Med. 117, 132–144.
99. Miyagawa T., Ebinuma I., Morohashi Y. et al. (2016) BIN1 regulates BACE1 intracellular trafficking and amyloid-β production. Hum. Mol. Genet. 14, 2948–2958.
100. Molander-Melin M., Blennow K., Bogdanovic N., Dellheden B., Mansson J. E. and Fredman P. (2005) Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J. Neurochem. 92, 171–182.
101. Moreau K., Fleming A., Imarisio S. et al. (2014) PICALM modulates autophagy activity and tau accumulation. Nat. Commun. 22, 4998.
102. Morel E., Chamoun Z., Lasiecka Z. M. et al. (2013) Phosphatidylinositol-3-phosphate regulates sorting and processing of amyloid precursor protein through the endosomal system. Nat. Commun., 4, 2250.
103. Mueller-Steiner S., Zhou Y., Arai H. et al. (2006) Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 51, 703–714.
104. Nakamura Y., Takeda M., Suzuki H., Hattori H., Tada K., Hariguchi S., Hashimoto S. and Nishimura T. (1991) Abnormal distribution of cathepsins in the brain of patients with Alzheimer's disease. Neurosci. Lett. 130, 195–198.
105. Nalls M. A., Duran R., Lopez G. et al. (2013) A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 70, 727–735.
106. Nishino I., Fu J., Tanji K. et al. (2000) Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 406, 906–910.
107. Nixon R. A. and Cataldo A. M. (2006) Lysosomal system pathways: genes to neurodegeneration in Alzheimer's disease. J. Alzheimers Dis. 9, 277–289.
108. Nixon R. A., Wegiel J., Kumar A., Yu W. H., Peterhoff C., Cataldo A. and Cuervo A. M. (2005) Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J. Neuropathol. Exp. Neurol. 64, 113–122.
109. Ohmi K., Zhao H. Z. and Neufeld E. F. (2011) Defects in the medial entorhinal cortex and dentate gyrus in the mouse model of Sanfilippo syndrome type B. PLoS ONE 6, e27461.
110. Orth M. and Mundegar R. R. (2003) Effect of acid maltase deficiency on the endosomal/lysosomal system and glucose transporter 4. Neuromuscul. Disord. 13, 49–54.
111. Pasternak S. H., Bagshaw R. D., Guiral M., Zhang S., Ackerley C. A., Pak B. J., Callahan J. W. and Mahuran D. J. (2003) Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane. J. Biol. Chem. 278, 26687–26694.
112. Patterson C., Feightner J. W., Garcia A., Hsiung G. Y., MacKnight C. and Sadovnick A. D. (2008) Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ 178, 548–556.
113. Pensalfini A., Albay R., 3rd, Rasool S. et al. (2014) Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques. Neurobiol. Dis. 71, 53–61.
114. Pentchev P. G., Comly M. E., Kruth H. S., Vanier M. T., Wenger D. A., Patel S. and Brady R. O. (1985) A defect in cholesterol esterification in Niemann-Pick disease (type C) patients. Proc. Natl Acad. Sci. USA 82, 8247–8251.
115. Peric A. and Annaert W. (2015) Early etiology of Alzheimer's disease: tipping the balance toward autophagy or endosomal dysfunction? Acta Neuropathol. 129, 363–381.
116. Pitto M., Raimondo F., Zoia C., Brighina L., Ferrarese C. and Masserini M. (2005) Enhanced GM1 ganglioside catabolism in cultured fibroblasts from Alzheimer patients. Neurobiol. Aging 26, 833–838.
117. Plassman B. L., Langa K. M., Fisher G. G. et al. (2007) Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 29, 125–132.
118. Podewils L. J., Guallar E., Kuller L. H., Fried L. P., Lopez O. L., Carlson M. and Lyketsos C. G. (2005) Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study. Am. J. Epidemiol. 161, 639–651.
119. Prasher V. P. and Krishnan H. R. (1993) Age of onset and duration of dementia in people with Down Syndrome: Integration of 98 reported cases in the literature. Int. J. Geriat. Psychiatry 8, 915–922.
120. Prasher V. P., Farrer M. J., Kessling A. M., Fisher E. M., West R. J., Barber P. C. and Butler A. C. (1998) Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann. Neurol. 43, 380–383.
121. Prince M., Wimo A., Guerchet M., Ali G.-C., Wu Y.-T. and Prina M. (2015) World Alzheimer Report. The Global Impact of Dementia, An Analysis of Prevalence, Incidence, Cost and Trends.
122. Rajendran L., Honsho M., Zahn T. R., Keller P., Geiger K. D., Verkade P. and Simons K. (2006) Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc. Natl Acad. Sci. USA 103, 11172–11177.
123. Ridge P. G., Mukherjee S., Crane P. K. and Kauwe J. S. (2013) Alzheimer's disease: analyzing the missing heritability. PLoS ONE 8, e79771.
124. Ritchie K., Kildea D. and Robine J. M. (1992) The relationship between age and the prevalence of senile dementia: a meta-analysis of recent data. Int. J. Epidemiol. 21, 763–769.
125. Saido T. and Leissring M. A. (2012) Proteolytic degradation of amyloid beta-protein. Cold Spring Harb. Perspect Med. 2, a006379.
126. Salehi A., Delcroix J. D., Belichenko P. V. et al. (2006) Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51, 29–42.
127. Sannerud R., Esselens C., Ejsmont P. et al. (2016) Restricted location of PSEN2/gamma-secretase determines substrate specificity and generates an intracellular abeta pool. Cell 166, 193–208.
128. Scarmeas N., Stern Y., Mayeux R. and Luchsinger J. A. (2006) Mediterranean diet, Alzheimer disease, and vascular mediation. Arch. Neurol. 63, 1709–1717.
129. Schwagerl A. L., Mohan P. S., Cataldo A. M., Vonsattel J. P., Kowall N. W. and Nixon R. A. (1995) Elevated levels of the endosomal-lysosomal proteinase cathepsin D in cerebrospinal fluid in Alzheimer disease. J. Neurochem. 64, 443–446.
130. Shie F. S., LeBoeuf R. C. and Jin L. W. (2003) Early intraneuronal Abeta deposition in the hippocampus of APP transgenic mice. NeuroReport 14, 123–129.
131. Siintola E., Partanen S., Stromme P., Haapanen A., Haltia M., Maehlen J., Lehesjoki A. E. and Tyynela J. (2006) Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. Brain 129, 1438–1445.
132. Sisodia S. S., Koo E. H., Beyreuther K., Unterbeck A. and Price D. L. (1990) Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing. Science, 248, 492–495.
133. Small S. A. and Gandy S. (2006) Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. Neuron 52, 15–31.
134. Smith K. R., Damiano J., Franceschetti S. et al. (2012) Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am. J. Hum. Genet. 90, 1102–1107.
135. Sokol J., Blanchette-Mackie J., Kruth H. S. et al. (1988) Type C Niemann-Pick disease. Lysosomal accumulation and defective intracellular mobilization of low density lipoprotein cholesterol. J. Biol. Chem. 263, 3411–3417.
136. Soriano S., Chyung A. S., Chen X., Stokin G. B., Lee V. M. and Koo E. H. (1999) Expression of beta-amyloid precursor protein-CD3gamma chimeras to demonstrate the selective generation of amyloid beta(1-40) and amyloid beta(1-42) peptides within secretory and endocytic compartments. J. Biol. Chem. 274, 32295–32300.
137. Spada M., Pagliardini S., Yasuda M., Tukel T., Thiagarajan G., Sakuraba H., Ponzone A. and Desnick R. J. (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am. J. Hum. Genet. 79, 31–40.
138. Suzuki K. and Terry R. D. (1967) Fine structural localization of acid phosphatase in senile plaques in Alzheimer's presenile dementia. Acta Neuropathol. 8, 276–284.
139. Tagawa K., Yazaki M., Kinouchi T., Maruyama K., Sorimachi H., Tsuchiya T., Suzuki K. and Ishiura S. (1993) Amyloid precursor protein is found in lysosomes. Gerontology 39(Suppl 1), 24–29.
140. Takahashi R. H., Milner T. A., Li F., Nam E. E., Edgar M. A., Yamaguchi H., Beal M. F., Xu H., Greengard P. and Gouras G. K. (2002) Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am. J. Pathol. 161, 1869–1879.
141. Takahashi R. H., Almeida C. G., Kearney P. F., Yu F., Lin M. T., Milner T. A. and Gouras G. K. (2004) Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J. Neurosci. 24, 3592–3599.
142. Takami M., Nagashima Y., Sano Y., Ishihara S., Morishima-Kawashima M., Funamoto S. and Ihara Y. (2009) gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J. Neurosci. 29, 13042–13052.
143. Taki T. (2012) An approach to glycobiology from glycolipidomics: ganglioside molecular scanning in the brains of patients with Alzheimer's disease by TLC-blot/matrix assisted laser desorption/ionization-time of flight MS. Biol. Pharm. Bull. 35, 1642–1647.
144. Tam J. H., Seah C. and Pasternak S. H. (2014) The Amyloid Precursor Protein is rapidly transported from the Golgi apparatus to the lysosome and where it is processed into beta-amyloid. Mol. Brain 7, 54.
145. Tamboli I. Y., Prager K., Barth E., Heneka M., Sandhoff K. and Walter J. (2005) Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide. J. Biol. Chem. 280, 28110–28117.
146. Tappino B., Biancheri R., Mort M. et al. (2010) Identification and characterization of 15 novel GALC gene mutations causing Krabbe disease. Hum. Mutat. 31, E1894–E1914.
147. Tiribuzi R., Orlacchio A., Crispoltoni L. et al. (2011) Lysosomal beta-galactosidase and beta-hexosaminidase activities correlate with clinical stages of dementia associated with Alzheimer's disease and type 2 diabetes mellitus. J. Alzheimers Dis. 24, 785–797.
148. Torres M., Jimenez S., Sanchez-Varo R. et al. (2012) Defective lysosomal proteolysis and axonal transport are early pathogenic events that worsen with age leading to increased APP metabolism and synaptic Abeta in transgenic APP/PS1 hippocampus. Mol. Neurodegener. 7, 59.
149. Udayar V., Buggia-Prevot V., Guerreiro R. L. et al. (2013) A paired RNAi and RabGAP overexpression screen identifies Rab11 as a regulator of beta-amyloid production. Cell Rep. 5, 1536–1551.
150. Ueno H., Yamaguchi T., Fukunaga S., Okada Y., Yano Y., Hoshino M. and Matsuzaki K. (2014) Comparison between the aggregation of human and rodent amyloid beta-proteins in GM1 ganglioside clusters. Biochemistry 53, 7523–7530.
151. Urbanelli L., Emiliani C., Massini C., Persichetti E., Orlacchio A., Pelicci G., Sorbi S., Hasilik A., Bernardi G. and Orlacchio A. (2008) Cathepsin D expression is decreased in Alzheimer's disease fibroblasts. Neurobiol. Aging 29, 12–22.
152. Vassar R., Bennett B. D., Babu-Khan S. et al. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735–741.
153. Wang H. X., Karp A., Winblad B. and Fratiglioni L. (2002) Late-life engagement in social and leisure activities is associated with a decreased risk of dementia: a longitudinal study from the Kungsholmen project. Am. J. Epidemiol. 155, 1081–1087.
154. Wang R. Y., Lelis A., Mirocha J. and Wilcox W. R. (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet. Med. 9, 34–45.
155. Wang C., Sun B., Zhou Y., Grubb A. and Gan L. (2012) Cathepsin B degrades amyloid-beta in mice expressing wild-type human amyloid precursor protein. J. Biol. Chem. 287, 39834–39841.
156. Wassif C. A., Cross J. L., Iben J. et al. (2016) High incidence of unrecognized visceral/neurological late-onset Niemann-Pick disease, type C1, predicted by analysis of massively parallel sequencing data sets. Genet. Med. 1, 41–48.
157. Wilson R. S., Bacon L. D., Fox J. H., Kramer R. L. and Kaszniak A. W. (1983) Word frequency effect and recognition memory in dementia of the Alzheimer type. J. Clin. Neuropsychol. 5, 97–104.
158. Wilson C. A., Murphy D. D., Giasson B. I., Zhang B., Trojanowski J. Q. and Lee V. M. (2004) Degradative organelles containing mislocalized alpha-and beta-synuclein proliferate in presenilin-1 null neurons. J. Cell Biol. 165, 335–346.
159. Wise D., Wallace H. J. and Jellinek E. H. (1962) Angiokeratoma corporis diffusum. A clinical study of eight affected families. Q J Med. 31, 177–206.
160. Wisniewski K. E., Dalton A. J., McLachlan C., Wen G. Y. and Wisniewski H. M. (1985) Alzheimer's disease in Down's syndrome: clinicopathologic studies. Neurology 35, 957–961.
161. Wisniewski K. E., Kida E., Gordon-Majszak W. and Saitoh T. (1990a) Altered amyloid beta-protein precursor processing in brains of patients with neuronal ceroid lipofuscinosis. Neurosci. Lett. 120, 94–96.
162. Wisniewski K. E., Maslinska D., Kitaguchi T., Kim K. S., Goebel H. H. and Haltia M. (1990b) Topographic heterogeneity of amyloid B-protein epitopes in brains with various forms of neuronal ceroid lipofuscinoses suggesting defective processing of amyloid precursor protein. Acta Neuropathol. 80, 26–34.
163. Wraith J. E. (2004) Clinical Aspects and Diagnosis. In Lysosomal Disorders of the Brain. Oxford University Press, Oxford.
164. Xiao Q., Yan P., Ma X. et al. (2015) Neuronal-targeted TFEB accelerates lysosomal degradation of APP, reducing abeta generation and amyloid plaque pathogenesis. J. Neurosci. 35, 12137–12151.
165. Xu Y. H., Xu K., Sun Y. et al. (2014) Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Hum. Mol. Genet. 23, 3943–3957.
166. Xue X., Wang L. R., Sato Y., Jiang Y., Berg M., Yang D. S., Nixon R. A. and Liang X. J. (2014) Single-walled carbon nanotubes alleviate autophagic/lysosomal defects in primary glia from a mouse model of Alzheimer's disease. Nano Lett. 14, 5110–5117.
167. Yanagisawa K. and Ihara Y. (1998) GM1 ganglioside-bound amyloid beta-protein in Alzheimer's disease brain. Neurobiol. Aging 19, S65–S67.
168. Yanagisawa K., Odaka A., Suzuki N. and Ihara Y. (1995) GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Nat. Med. 1, 1062–1066.
169. Yang D. S., Stavrides P., Mohan P. S. et al. (2011) Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain 134, 258–277.
170. Yang R., Wang Q., Min L., Sui R., Li J. and Liu X. (2013) Monosialoanglioside improves memory deficits and relieves oxidative stress in the hippocampus of rat model of Alzheimer's disease. Neurol. Sci. 34, 1447–1451.
171. Yang D. S., Stavrides P., Saito M. et al. (2014) Defective macroautophagic turnover of brain lipids in the TgCRND8 Alzheimer mouse model: prevention by correcting lysosomal proteolytic deficits. Brain 137, 3300–3318.
172. Yu W. H., Kumar A., Peterhoff C., Shapiro Kulnane L., Uchiyama Y., Lamb B. T., Cuervo A. M. and Nixon R. A. (2004) Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities: implications for beta-amyloid peptide over-production and localization in Alzheimer's disease. Int. J. Biochem. Cell Biol. 36, 2531–2540.
173. Yu W. H., Cuervo A. M., Kumar A. et al. (2005) Macroautophagy–a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease. J. Cell Biol. 171, 87–98.
174. Yu C. E., Bird T. D., Bekris L. M. et al. (2010) The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch. Neurol. 67, 161–170.